Sutro Biopharma (Sutro Biopharma) Revenue per Share : $2.53 (TTM As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Sutro Biopharma Revenue per Share?

Sutro Biopharma's revenue per share for the three months ended in Mar. 2024 was $0.21. Sutro Biopharma's revenue per share for the trailing twelve months (TTM) ended in Mar. 2024 was $2.53.

Warning Sign:

Sutro Biopharma Inc revenue per share has been in decline for the last 5 years.

During the past 12 months, the average Revenue Per Share Growth Rate of Sutro Biopharma was 75.00% per year. During the past 3 years, the average Revenue Per Share Growth Rate was 24.90% per year. During the past 5 years, the average Revenue Per Share Growth Rate was -15.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.

The historical rank and industry rank for Sutro Biopharma's Revenue per Share or its related term are showing as below:

STRO' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -43.8 Med: -39.8 Max: 24.9
Current: 24.9

During the past 8 years, Sutro Biopharma's highest 3-Year average Revenue Per Share Growth Rate was 24.90% per year. The lowest was -43.80% per year. And the median was -39.80% per year.

STRO's 3-Year Revenue Growth Rate is ranked better than
74.87% of 776 companies
in the Biotechnology industry
Industry Median: 3.65 vs STRO: 24.90

Sutro Biopharma Revenue per Share Historical Data

The historical data trend for Sutro Biopharma's Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sutro Biopharma Revenue per Share Chart

Sutro Biopharma Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Revenue per Share

Get a 7-Day Free Trial

1.86

1.31

1.34

2.56

Sutro Biopharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Revenue per Share	Get a 7-Day Free Trial															0.22	0.17	0.28	1.87	0.21

Competitive Comparison of Sutro Biopharma's Revenue per Share

For the Biotechnology subindustry, Sutro Biopharma's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sutro Biopharma's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sutro Biopharma's PS Ratio distribution charts can be found below:

* The bar in red indicates where Sutro Biopharma's PS Ratio falls into.

Sutro Biopharma Revenue per Share Calculation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Sutro Biopharma's Revenue Per Share for the fiscal year that ended in Dec. 2023 is calculated as

Revenue Per Share (A: Dec. 2023 )	=	Revenue (A: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2023 )
	=	153.731	/	60.164
	=	2.56

Sutro Biopharma's Revenue Per Share for the quarter that ended in Mar. 2024 is calculated as

Revenue Per Share (Q: Mar. 2024 )	=	Revenue (Q: Mar. 2024 )	/	Shares Outstanding (Diluted Average) (Q: Mar. 2024 )
	=	13.008	/	61.458
	=	0.21

Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.53

Sutro Biopharma (NAS:STRO) Revenue per Share Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.

Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.

Sutro Biopharma Revenue per Share Related Terms

Thank you for viewing the detailed overview of Sutro Biopharma's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Sutro Biopharma (Sutro Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sutro Biopharma Inc (NAS:STRO) » Definitions » Revenue per Share

Comparable Companies

Traded in Other Exchanges

S09:Germany S09:Germany

Address

111 Oyster Point Boulevard, South San Francisco, CA, USA, 94080

Website

https://www.sutrobio.com

Sutro Biopharma Inc is clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.

Executives

Hans-peter Gerber	officer: Chief Scientific Officer	C/O SUTRO BIOPHARMA, INC., 111 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Brunilda Shtylla	officer: Chief Business Officer	C/O SUTRO BIOPHARMA, INC., 111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA 94080
Venkatesh Srinivasan	officer: Chief Tech Op Officer	C/O SUTRO BIOPHARMA, INC., 111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA 94080
Anne Elizabeth Borgman	officer: Chief Medical Officer	9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
William J Newell	director, officer: CEO & President	887 GREAT NORTHERN WAY, VANCOUVER A1 V5T 4T5
Heidi Hunter	director	C/O SUTRO BIOPHARMA, INC., 310 UTAH AVE., SUITE 150, SOUTH SAN FRANCISCO CA 94080
Nicki Vasquez	officer: Chief Port. Strat & Alnce Ofcr	C/O SUTRO BIOPHARMA, INC., 310 UTAH AVE., SUITE 150, SOUTH SAN FRANCISCO CA 94080
Jane Chung	officer: Chief Commercial Officer	C/O SUTRO BIOPHARMA, INC., 310 UTAH AVE., SUITE 150, SOUTH SAN FRANCISCO CA 94080
Trevor Hallam	officer: Chief Science Officer	PALATIN TECHNOLOGIES, INC., 4C CEDAR BROOK DRIVE, CRANBURY NJ 08512
Jon Marc Wigginton	director	9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
John Gordon Freund	director, 10 percent owner	125 UNIVERSITY AVE., C/O SKYLINE VENTURES, PALO ALTO CA 94301
Arturo Md Molina	officer: Chief Medical Officer	10990 WILSHIRE BLVD, SUITE 1200, LOS ANGELES CA 90024
Linda A Fitzpatrick	officer: Chief People & Comm. Officer	NUVELO, INC., 675 ALMANOR AVENUE, SUNNYVALE CA 94085
James P Panek	director	C/O VAXGEN INC, 1000 MARINA BLVD. #200, BRISBANE CA 94005
Matsui Connie	director	3030 CALLAN RD, SAN DIEGO CA 92121